Further to intimations dated 7th & 11th October, 2019 with regard to the USFDA inspection of Unit VII, an oral solids formulation manufacturing facility of the Company, Aurobindo Pharma has informed that the Company has received a letter from the USFDA classifying the inspection conducted at the aforesaid facility as Official Action Indicated (OAI). This OAI classification will not have any material impact on the existing revenues or the supplies to its US business at this juncture. The Company will work closely with the regulator to comprehensively address the issues.
The above information is a part of company’s filings submitted to BSE.
